Internal Medicine Alert
RSSArticles
-
Ombitasvir, Paritaprevir, and Ritonavir, Dasabuvir Tablets (Viekira™ Pak)
The FDA has approved the fourth new product for the treatment of chronic hepatitis C (HCV) infection since November 2013. The latest is a four fixed-drug combination (3-DAA) that includes paritaprevir, a nonstructure 3/4A protease inhibitor, ombitasvir, an inhibitor of the NS5A replication complex, and copackaged with dasabuvir, a nonnucleoside NS5B polymerase inhibitor. The plasma levels of paritaprevir is boosted with ritonavir, a CYP3A inhibitor to permit once-daily dosing. The combination is marketed by AbbVie, Inc. as Viekira Pak.
-
Can Intracardiac Echo Be Used as a Substitute for Transesophageal Echo Prior to Atrial Fibrillation Ablation?
This article originally appeared in the January 2015 issue of Clinical Cardiology Alert.
-
Should Metformin Use In Patients With Chronic Kidney Disease Be Expanded?
SYNOPSIS: Expansion of the metformin label to include patients with mild-to-moderate kidney disease is appropriate.
-
Nonsteroidal Anti-inflammatory Drug Use and Risk of Atrial Fibrillation
SYNOPSIS: Use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of incident atrial fibrillation, especially among new users of NSAIDs.
-
Clinical Briefs
Topics: Metformin: Have we Been Overcautious in CKD?, Reduction in Prostate, and Doing the Right Thing for Acute Bronchitis in Healthy Adults: Antibiotics
-
Edoxaban Tablets (Savaysa™)
The third oral factor Xa inhibitor has been approved by the FDA. Edoxaban is the fourth target-specific oral anticoagulant (TSOA) to enter the market following dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Edoxaban is manufactured by Tokyo-based Daiichi Sankyo Company and marketed by Daiichi Sankyo as Savaysa.
-
The Economic Burden of Undiagnosed Pre-diabetes
The economic burden of diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes has exceeded $322 billion.
-
Treatment of C. Difficile — Follow the Guidelines
ABSTRACT & COMMENTARY: The primary outcome was the occurrence of complications, including relapse within four weeks, surgery, and 30-day mortality.
-
Should Clinicians Discuss Resumption of Sexual Activity Following an Acute MI?
Although the U.S. and European cardiovascular society guidelines recommend that patients be counseled about resuming sexual activity after suffering an acute myocardial infarction (AMI), the actual demographics of sexual education post-myocardial infarction (MI) are unknown.
-
Can Answering a Phone Call Give You Cancer?
In the past decade, cellular phone usage has grown exponentially worldwide, and this use is prevalent in all age groups, including children.